Pharming granted EU backing for rare immunodeficiency therapy
Source: SeekingAlpha
2026-03-27 12:10:30 ET
More on Pharming
- Pharming Group N.V. 2025 Q4 - Results - Earnings Call Presentation
- Pharming Group N.V. (PHAR) Q4 2025 Earnings Call Transcript
- Pharming Group N.V. (PHAR) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference - Slideshow
- Pharming outlines $405M–$425M 2026 revenue target as Joenja and RUCONEST drive growth
- Pharming beats top-line estimates; introduces FY26 outlook
Read the full article on Seeking Alpha
For further details see:
Pharming granted EU backing for rare immunodeficiency therapy
Pharming Group N.V.
NASDAQ: PHAR
PHAR Trading
0.22% G/L:
$13.75 Last:
10,510 Volume:
$13.79 Open:
PHAR Latest News
$1,106,258,522
65,794,170
N/A
5
N/A
Biotechnology & Life Sciences
Healthcare
NL
Leiden
